VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 87 filers reported holding VAXCYTE INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $10,712,582 | -11.0% | 210,133 | -12.8% | 0.00% | 0.0% |
| Q2 2023 | $12,040,683 | +13.1% | 241,103 | -15.1% | 0.00% | 0.0% |
| Q1 2023 | $10,648,404 | -25.1% | 284,109 | -4.2% | 0.00% | -50.0% |
| Q4 2022 | $14,222,882 | +456.5% | 296,619 | +178.6% | 0.00% | – |
| Q3 2022 | $2,556,000 | +22.0% | 106,455 | +10.5% | 0.00% | – |
| Q2 2022 | $2,095,000 | +125.5% | 96,304 | +150.3% | 0.00% | – |
| Q1 2022 | $929,000 | -48.0% | 38,478 | -48.7% | 0.00% | – |
| Q4 2021 | $1,785,000 | +149.3% | 75,067 | +165.9% | 0.00% | – |
| Q3 2021 | $716,000 | -59.5% | 28,233 | -64.1% | 0.00% | – |
| Q2 2021 | $1,770,000 | +81.9% | 78,611 | +59.6% | 0.00% | – |
| Q1 2021 | $973,000 | +946.2% | 49,267 | +1297.2% | 0.00% | – |
| Q4 2020 | $93,000 | -49.2% | 3,526 | -4.8% | 0.00% | – |
| Q3 2020 | $183,000 | +2950.0% | 3,705 | +1752.5% | 0.00% | – |
| Q2 2020 | $6,000 | – | 200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 1,049,893 | $53,523,545 | 17.09% |
| Pivotal bioVenture Partners Investment Advisor LLC | 793,036 | $40,429,128 | 16.12% |
| Kynam Capital Management, LP | 1,302,407 | $66,396,709 | 10.86% |
| RA Capital Management | 7,891,254 | $402,296,129 | 7.92% |
| COMMODORE CAPITAL LP | 1,100,000 | $56,078,000 | 6.56% |
| GREAT POINT PARTNERS LLC | 531,211 | $27,081,137 | 4.93% |
| ACUTA CAPITAL PARTNERS, LLC | 121,022 | $6,169,702 | 4.14% |
| Frazier Life Sciences Management, L.P. | 1,164,405 | $59,361,367 | 3.94% |
| Novo Holdings A/S | 845,000 | $43,078,100 | 3.18% |
| BRAIDWELL LP | 1,619,553 | $82,564,812 | 2.61% |